Dr. Paul F. Schellhammer

• 
  www.ProstateCancerUpdate.com/2003/3/default.htm - [Cached Version]
  Published on: 1/1/2003    Last Visited: 8/15/2008  

  Paul F Schellhammer, MD

• 
  www.intelihealth.com/IH/ihtIH/WSIHW000/333/7228/1330255 - [Cached Version]
  Published on: 4/28/2009    Last Visited: 5/8/2009  

  "There have been a lot of false starts, but this is a real start," said Dr. Paul Schellhammer, a urologist at Eastern Virginia Medical School in Norfolk, Va., who led the study. Results were reported Tuesday at an American Urological Association conference in Chicago.
  
  Seattle-based Dendreon paid for the study, and Schellhammer owns stock in the company. Dendreon shares fell sharply, and then trading was halted leading up to the release of the data. Shares fell $9.74, or 45.2 percent, to $11.81.

• 
  investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=87739 - [Cached Version]
  Published on: 8/9/2002    Last Visited: 3/2/2007  

  "Gleason grade is the most powerful prognostic factor driving virtually all algorithms for pathologic outcome and clinical prognosis," said Paul Schellhammer, M.D., professor and chief of urology at Eastern Virginia Medical School.

• 
  www.swiu.org/meetings/2007/aua.aspx - [Cached Version]
  Published on: 1/1/2006    Last Visited: 4/28/2007  

  Paul F. Schellhammer, M.D., President-Elect, AUA

• 
  www.ProstateCancerUpdate.com/2003/3/schellhammer.htm - [Cached Version]
  Published on: 1/1/2003    Last Visited: 8/15/2008  

  Paul F Schellhammer, MDProstate Cancer Update 3 | 2003
  ...
  Home: PCU 3|2003: Paul F Schellhammer, MD
  ...
  Paul F Schellhammer, MD
  
  Program Director, Virginia Prostate CenterProfessor of Urology, Eastern Virginia Medical School and Sentara Cancer Institute
  
  Trustee, American Board of Urology
  
  Edited comments by Dr Schellhammer
  ...
  Paul F Schellhammer, MD

• 
  www.iaua.net/index.php?p=blog - [Cached Version]
  Last Visited: 9/10/2008  

  The last meeting was also attended by several dignitaries including AUA president, Dr. Paul Schellhammer.

• 
  medicalfront-page.com/?paged=2 - [Cached Version]
  Last Visited: 2/27/2009  

  "Although a large clinical trial has shown that 5-ARIs can decrease the incidence of prostate cancer, we are still not able to determine if the mortality from prostate cancer is reduced," said Paul F. Schellhammer, MD, a past president of the AUA and co-chair of the panel that developed the guideline.

• 
  www.prostatecancerupdate.net/2006/3/schellhammer_sp.asp - [Cached Version]
  Published on: 1/1/2006    Last Visited: 5/17/2007  

  You are here: Home: PCU 3 | 2006: Paul F Schellhammer, MD: Select publications
  ...
  Paul F Schellhammer, MD

• 
  www.ProstateCancerUpdate.com/2003/3/editor.htm - [Cached Version]
  Published on: 1/1/2003    Last Visited: 8/15/2008  

  In terms of "issues that perplex everyday practitioners," you may wish to review the enclosed interview with Dr Paul Schellhammer — our first interviewee when we launched this series last year.Dr Schellhammer, a nationally recognized prostate cancer research leader, recounted his own personal challenging experience with radical prostatectomy (including the rare complication of a psoas abscess).At that time, he was also struggling with the knowledge that his PSA was rising.In the enclosed follow-up interview, he recounts his decision to be treated with pelvic radiotherapy and eight months of combined androgen blockade.
  ...
  Paul F Schellhammer, MD

• 
  www.ProstateCancerUpdate.com/2003/3/zietman.htm - [Cached Version]
  Published on: 1/1/2003    Last Visited: 8/15/2008  

  Paul Schellhammer and I recently reported on a couple of hundred patients with prostate cancer in their early 70s, each with a comorbid condition, who did not receive radical treatment.
  ...
  Paul F Schellhammer, MD

Page:  1 2 3 4 5